Chaqour B (2020) Caught between a "rho" and a hard place: are CCN1/CYR61 and CCN2/CTGF the arbiters of microvascular stiffness? J Cell Commun Signal 14(1):21–29
Ju L, Sun Y, Xue H, Chen L, Gu C, Shao J, Lu R, Luo X, Wei J, Ma X, Bian Z (2020) CCN1 promotes hepatic steatosis and inflammation in non-alcoholic steatohepatitis. Sci Rep 10(1):3201
Kulkarni T, Kurundkar AR, Kim YI, de Andrade J, Luckhardt T, Thannickal VJ (2020) The senescence-associated matricellular protein CCN1 in plasma of human subjects with idiopathic pulmonary fibrosis. Respir Med 161:105821
Leask A (2020a) Conjunction junction, what's the function? CCN proteins as targets in fibrosis and cancers. Am J Physiol Cell Physiol 318(6):C1046–C1054
Leask A (2020b) A centralized communication network: recent insights into the role of the cancer associated fibroblast in the development of drug resistance in tumors. Semin Cell Dev Biol 101:111–114
Leask A, Holmes A, Black CM, Abraham DJ (2003) Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem 278(15):13008–13015
Moon S, Lee S, Caesar JA, Pruchenko S, Leask A, Knowles JA, Sinon J, Chaqour B (2020) A CTGF-YAP regulatory pathway is essential for angiogenesis and Barriergenesis in the retina. iScience 23(6):101184
Peidl A, Perbal B, Leask A (2019) Yin/Yang expression of CCN family members: transforming growth factor beta 1, via ALK5/FAK/MEK, induces CCN1 and CCN2, yet suppresses CCN3, expression in human dermal fibroblasts. PLoS One 14(6):e0218178
Perbal B (2018) The concept of the CCN protein family revisited: a centralized coordination network. J Cell Commun Signal 12(1):3–12
Quesnel K, Shi-wen X, Hutchenreuther J, Xiao Y, Liu S, Peidl A, Naskar D, Siqueira WL, O'Gorman DB, Hinz B, Stratton RJ, Leask A, (2019) CCN1 expression by fibroblasts is required for bleomycin-induced skin fibrosis, Matrix Biol Plus 3, 2019,
Riser BL, Najmabadi F, Perbal B, Peterson DR, Rambow JA, Riser ML, Sukowski E, Yeger H, Riser SC (2009) CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. Am J Pathol 174(5):1725–1734